• Advancing precision medicine with the next generation of RNA diagnostics

Cellgen is developing a novel precision medicine platform that enables doctors to administer a simple blood test that will determine if a person’s genetic profile is a match for a given therapeutic in 2 hours. This platform will help clinicians guide ongoing treatment decisions to make sure the right person is taking the right medicine. Each disposable test will not only be guided by the genetics of each patient, but also by the latest clinical knowledge on drug metabolism.  Cellgen’s decision support and computational algorithms will provide a predictive analysis of the therapeutic effectiveness, where every new patient improves the predictive accuracy. Cellgen’s speed, simplicity and low cost will allow clinicians, to both, administer and process non-invasive, genomic based testing at the point of care. If precision medicine is going to meet its promise and gain broad applicability, genomic technologies will have to meet patients at the point of care and move beyond Oncology.

The Value of RNA Based Diagnostics

DNA mutations, amplifications and deletions have proven to be limited to a subset of the population, leaving the majority of the patients without any biologically matched treatment option. And even if you do have the mutation, that doesn’t guarantee you will get the disease. DNA is the blueprint of life, but has very little to say about the current biological state of the body. RNA, on the other hand, is a dynamic diagnostic indicator of health providing real time snapshots of what’s happening in the body today. By leveraging RNA information from the patient, we are able to address all patients and gain knowledge about the role of the transcriptome in diagnosing disease and selecting targeted therapies for patients. Comparing differentially expressed gene levels allows for the characterization of disease in a way that is much more comprehensive and clinically relevant than straight detection of DNA aberrations alone.

Cellgen’s Approach

To improve global healthcare by partnering with care providers and insurance payers to deliver the gold standard in precision medicine diagnostics. Cellgen will enable clinicians to initiate, monitor and optimize a patient’s therapeutic treatment plan based on a patients individual genetics.

Cellgen's Twitter avatar

Agilent (A) Gets FDA Approval for Cervical Cancer Test Assay - June 14, 2018 - t.co/gZn5l7x30u t.co/uqvDmF4UoG